EE9600192A - Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine - Google Patents
Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamineInfo
- Publication number
- EE9600192A EE9600192A EE9600192A EE9600192A EE9600192A EE 9600192 A EE9600192 A EE 9600192A EE 9600192 A EE9600192 A EE 9600192A EE 9600192 A EE9600192 A EE 9600192A EE 9600192 A EE9600192 A EE 9600192A
- Authority
- EE
- Estonia
- Prior art keywords
- antibodies
- bind
- insect gut
- proteins
- gut proteins
- Prior art date
Links
- 241000238631 Hexapoda Species 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- C07K14/325—Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
- C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
- C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
- C12N15/8286—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for insect resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
- Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Pest Control & Pesticides (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Insects & Arthropods (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Agronomy & Crop Science (AREA)
- Virology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26764194A | 1994-06-28 | 1994-06-28 | |
PCT/IB1995/000497 WO1996000783A1 (en) | 1994-06-28 | 1995-06-20 | Antibodies which bind to insect gut proteins and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
EE9600192A true EE9600192A (et) | 1997-06-16 |
Family
ID=23019624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EE9600192A EE9600192A (et) | 1994-06-28 | 1995-06-20 | Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine |
Country Status (16)
Country | Link |
---|---|
US (2) | US5686600A (et) |
EP (1) | EP0804579A1 (et) |
JP (1) | JPH11505401A (et) |
CN (1) | CN1151759A (et) |
AU (1) | AU696661B2 (et) |
BG (1) | BG101171A (et) |
BR (1) | BR9508154A (et) |
CA (1) | CA2193859A1 (et) |
CZ (1) | CZ382196A3 (et) |
EE (1) | EE9600192A (et) |
HU (1) | HUT76089A (et) |
MX (1) | MX9700007A (et) |
NZ (1) | NZ287124A (et) |
PL (1) | PL318164A1 (et) |
SK (1) | SK166996A3 (et) |
WO (1) | WO1996000783A1 (et) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0879293A1 (de) * | 1996-02-08 | 1998-11-25 | Institut Für Pflanzengenetik Und Kulturpflanzenforschung | Kassetten zur expression von lagerstabilen proteinen in pflanzen |
CA2286284A1 (en) * | 1997-04-03 | 1998-10-08 | Novartis Ag | Plant pest control |
US7011835B1 (en) | 1997-07-10 | 2006-03-14 | Research Development Foundation | Targeted destruction of pests |
US6013510A (en) * | 1997-09-25 | 2000-01-11 | Becton, Dickinson And Company | Identification of a DNA region potentially useful for the detection of Mycobacterium kansasii |
US7250494B2 (en) * | 1998-06-15 | 2007-07-31 | Biosynexus Incorporated | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
US6187558B1 (en) | 1998-06-24 | 2001-02-13 | Boyce Thompson Institute For Plant Research, Inc. | Invertebrate intestinal mucin cDNA and related products and methods |
CA2331921A1 (en) * | 1998-06-24 | 1999-12-29 | Boyce Thompson Institute For Plant Research, Inc. | A novel invertebrate intestinal mucin cdna and related products and methods |
BR9915543A (pt) * | 1998-10-16 | 2001-08-14 | Fraunhofer Ges Forschung | Resistência a doenças por plantas mediada por patogenicidas moleculares |
WO2001058955A1 (en) * | 2000-02-10 | 2001-08-16 | Research Development Foundation | Targeted destruction of pests |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US9364565B2 (en) | 2000-03-15 | 2016-06-14 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
US7465790B2 (en) * | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
US6716421B2 (en) | 2001-03-05 | 2004-04-06 | University Of Florida Research Foundation, Inc. | Devices and methods for eliminating termite colonies |
US7030156B2 (en) | 2001-03-05 | 2006-04-18 | University Of Florida Research Foundation, Inc | Devices and methods for eliminating termite colonies |
US6969512B2 (en) | 2001-03-05 | 2005-11-29 | The University Of Florida Research Foundation, Inc. | Devices and methods for eliminating termite colonies |
EP1572866A4 (en) * | 2001-03-23 | 2008-01-16 | Syngenta Participations Ag | INSECT NUCLEAR RECEPTOR GENES AND USES THEREOF |
GB0119274D0 (en) * | 2001-08-08 | 2001-10-03 | Univ Durham | Fusion proteins for insect control |
US20040052779A1 (en) * | 2001-12-21 | 2004-03-18 | Stinson Jeffrey R. | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
US20040063912A1 (en) * | 2002-03-15 | 2004-04-01 | The Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
US20040016004A1 (en) * | 2002-04-01 | 2004-01-22 | Raitano Arthur B. | Nucleic acid and corresponding protein entitled 238P1B2 useful in treatment and detection of cancer |
EP2090591A3 (en) * | 2002-04-22 | 2009-10-28 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Antibodies, recombinant antibodies, recombinant antibody fragments and fusions mediated plant disease resistance against fungi |
US8029803B2 (en) * | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
EP1948802A4 (en) * | 2005-10-13 | 2009-01-14 | Virexx Medical Corp | CHIMERIC ANTIGEN WITH HEPATITIS C VIRUS POLYPEPTIDE AND FC FRAGMENT FOR CALLING UP AN IMMUNE RESPONSE |
US8415271B2 (en) * | 2007-04-21 | 2013-04-09 | Uxmal S.A. | Biofertilizer formulation |
US7879326B2 (en) * | 2007-06-15 | 2011-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Human neutralizing monoclonal antibodies to H5N1 influenza A virus |
US20090148904A1 (en) * | 2007-11-13 | 2009-06-11 | Mayfield Stephen P | Production of cytotoxic antibody-toxin fusion in eukaryotic algae |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3415010A1 (en) * | 2017-06-13 | 2018-12-19 | Agrosavfe Nv | Insect-controlling polypeptides and methods |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5290914A (en) * | 1988-04-28 | 1994-03-01 | Mycogen Corporation | Hybrid diphtheria-B.t. pesticidal toxins |
US5196320A (en) * | 1989-09-20 | 1993-03-23 | Abbott Biotech, Inc. | Method of producing engineered binding proteins |
US5202422A (en) * | 1989-10-27 | 1993-04-13 | The Scripps Research Institute | Compositions containing plant-produced glycopolypeptide multimers, multimeric proteins and method of their use |
EP0438312A3 (en) * | 1990-01-19 | 1992-07-01 | Merck & Co. Inc. | Recombinant human anti-cd18 antibodies |
US5143905A (en) * | 1990-05-03 | 1992-09-01 | The Regents Of The University Of California | Method and means for extending the host range of insecticidal proteins |
US5665595A (en) * | 1991-06-07 | 1997-09-09 | Dowelanco | Immunoglobulins against insect tissue |
DE59205079D1 (de) * | 1991-07-25 | 1996-02-29 | Ciba Geigy Ag | Immunologisches Nachweisverfahren |
-
1995
- 1995-05-16 US US08/442,542 patent/US5686600A/en not_active Expired - Fee Related
- 1995-06-20 BR BR9508154A patent/BR9508154A/pt not_active Application Discontinuation
- 1995-06-20 AU AU25735/95A patent/AU696661B2/en not_active Ceased
- 1995-06-20 PL PL95318164A patent/PL318164A1/xx unknown
- 1995-06-20 CN CN95193817A patent/CN1151759A/zh active Pending
- 1995-06-20 EE EE9600192A patent/EE9600192A/et unknown
- 1995-06-20 MX MX9700007A patent/MX9700007A/es unknown
- 1995-06-20 CA CA002193859A patent/CA2193859A1/en not_active Abandoned
- 1995-06-20 WO PCT/IB1995/000497 patent/WO1996000783A1/en not_active Application Discontinuation
- 1995-06-20 JP JP8502979A patent/JPH11505401A/ja active Pending
- 1995-06-20 HU HU9603526A patent/HUT76089A/hu unknown
- 1995-06-20 EP EP95920192A patent/EP0804579A1/en not_active Withdrawn
- 1995-06-20 SK SK1669-96A patent/SK166996A3/sk unknown
- 1995-06-20 NZ NZ287124A patent/NZ287124A/en unknown
- 1995-06-20 US US08/765,469 patent/US6069301A/en not_active Expired - Fee Related
- 1995-06-20 CZ CZ963821A patent/CZ382196A3/cs unknown
-
1997
- 1997-01-24 BG BG101171A patent/BG101171A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BG101171A (en) | 1997-10-31 |
NZ287124A (en) | 1999-04-29 |
PL318164A1 (en) | 1997-05-26 |
JPH11505401A (ja) | 1999-05-21 |
AU2573595A (en) | 1996-01-25 |
CN1151759A (zh) | 1997-06-11 |
CA2193859A1 (en) | 1996-01-11 |
EP0804579A1 (en) | 1997-11-05 |
US5686600A (en) | 1997-11-11 |
HUT76089A (en) | 1997-06-30 |
AU696661B2 (en) | 1998-09-17 |
MX9700007A (es) | 1997-04-30 |
US6069301A (en) | 2000-05-30 |
BR9508154A (pt) | 1998-07-14 |
WO1996000783A1 (en) | 1996-01-11 |
SK166996A3 (en) | 1997-08-06 |
CZ382196A3 (cs) | 1998-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE9600192A (et) | Antikehad, mis seostuvad putuka soole valkudele, ja nende kasutamine | |
EE05538B1 (et) | Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine | |
FI963185A (fi) | Hematopoieettinen proteiini ja materiaalit ja menetelmät sen valmistamiseksi | |
FI951801A (fi) | CTLA4-molekyylit ja IL4:sitovat molekyylit sekä näiden käyttö | |
DE69232604D1 (de) | Antikörperkonstrukte | |
NO985464D0 (no) | Konsentrert antistoffpreparat | |
FI972165A (fi) | Aerogeelipitoinen komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö | |
DE69617896D1 (de) | Humaner monoklonaler Antikörper gegen VEGF | |
BR9606889A (pt) | Toxinas proteicas inseticidas de photorhabdus | |
BR9610404A (pt) | Anticorpos anti-cd4 recombinantes para terapia humana | |
DE29517190U1 (de) | Analyse- und Dosiersystem | |
EE9900147A (et) | Oksadiasoolid, nende saamismeetodid ja kasutamine ravimitena | |
FI972245A0 (fi) | Meso-monojodisubstituoidut tetramakrosykliset yhdisteet sekä niiden valmistus- ja käyttömenetelmät | |
DE69531958D1 (de) | (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper | |
TR199600371A2 (tr) | Organosilan bilesiklerinin harmanlari ve bunlarin kullanimi. | |
FI951726A (fi) | Boronihappopeptidijohdannaisia, niiden valmistus ja käyttö synteesivälituotteina | |
DE69232307D1 (de) | Endotoxinbindendes und -neutralisierendes protein und verwendungen dafür | |
BR9606951A (pt) | Proteinas matantes | |
DE3888604D1 (de) | Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen. | |
FI953391A (fi) | Komposiittimateriaali, menetelmä sen valmistamiseksi ja sen käyttö | |
EE9900092A (et) | PTX-tundlikud G-valgud, nende valmistamine ja kasutamine | |
FI953257A0 (fi) | Rekombinanttinen ihmisen prostaspesifinen antigeenRekombinanttinen ihmisen prostaspesifinen antigeeni ja sen käytöt i ja sen käytöt | |
DE3687542D1 (de) | Monoklonaler antikoerper gegen humanes protein c. | |
DE69526143T2 (de) | Abtrennfreier, spezifischer Bindungsassay mit Anti-Inhibitor-Antikörpern | |
LV11542A (lv) | Aizvietoti 1,3,9,11-tetraoksa-4,5,7,8-tetraazaundekadien-4,7-dioksidi- 5,7 ,to iegusana un pielietosana |